儿科复发/耐性ALK阳性ALCL的不常见表现和治疗策略
Samanta Catueno1, Maria Frost1, Branko Cuglievan1
1Department of Pediatrics, Pediatric Hematology-Oncology.
Journal of pediatric hematology/oncology
|March 12, 2026
概括
具有二次性血细胞性淋巴细胞瘤 (HLH) 的无塑性大细胞淋巴瘤 (ALCL) 存在治疗挑战. 向治疗和干细胞移植为复发或高风险ALK阳性ALCL的缓解提供了希望.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 儿科瘤学 儿科瘤学
背景情况:
- 无细胞大细胞淋巴瘤 (ALCL) 是一种具有攻击性的T细胞恶性瘤.
- 二次性血液细胞性淋巴细胞细胞瘤 (HLH) 是ALCL的一种罕见但严重的并发症.
研究的目的:
- 描述一个具有挑战性的ALK阳性ALCL与儿科患者同时出现HLH的病例.
- 突出针对性疗法和多学科治疗在实现缓解方面的作用.
主要方法:
- 一个6岁男孩的病例报告,诊断出ALK阳性ALCL和HLH.
- 治疗包括重症监护,化疗,向药物 (克里佐替尼布,鲁克索利替尼布),德克萨米他和全原干细胞移植.
- 需要对多次复发进行管理.
主要成果:
- 患者经历了多次复发,需要密集治疗.
- 最终通过向疗法和全原干细胞移植的结合,成功地实现了缓解.
- 这一案例凸显了管理ALCL-HLH的复杂性.
结论:
- 具有ALK阳性的ALCL与并发的HLH构成了重大的临床挑战.
- 向治疗,如crizotinib和 ruxolitinib,在管理复发性或耐药性疾病方面发挥着至关重要的作用.
- 新型药物的分子理解和整合方面的进展对于改善高风险ALCL的结果至关重要.
关键词:
在ALCL和ALCL之间.HLHH HLHH 这是一个很好的例子.布伦图克西马巴 (brentuximab) 是一个克里佐丁尼布 (crizotinib) 的使用方法儿科 儿科 儿科 儿科卢克索利提尼布 (Ruxolitinib) 是一种药物.更多相关视频
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.9K
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.9K
相关概念视频
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K